At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...

AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Accurately tracking trial initiations has often been a challenge because start dates are not always disclosed or are reported incorrectly. Credit: Ihar Halavach via Shutterstock.com. According to ...

The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...

Aditya Kotta discussed the biotech funding environment and market trends at OCTSC meeting, in San Diego, California, US. Credits: Athanasios Psimadis / Arena International. The biotech sector has ...

In this edition of Trials to Watch, Clinical Trials Arena looks into the potential of three drugs in Phase III development for the autoimmune neurological condition, multiple sclerosis (MS). Image ...

Zenas BioPharma’s investigational relapsing multiple sclerosis (RMS) asset, obexelimab, has met its primary endpoint in the Phase II MoonStone trial. Image credit: OksanaFedorchuk via Shutterstock.com ...